2012-11-28 16:14:31 -
A number of stocks were upgraded and downgraded by equities research analysts
today, as reported by Analyst Ratings Network ( bit.ly/equitybriefdaily)
and Equity Brief:
Morgan Stanley upgraded shares of Companhia Energetica de MinasGerais (NYSE:
CIG) from an equal weight rating to an overweight rating.
Zacks reiterated its neutral rating on shares of Rockwell Collins (NYSE: COL).
They have a $59.00 price target on the stock. Zacks' analyst wrote, "Rockwell
Collins is the foremost global supplier of communications and avionics equipment
for both commercial and military customers. The company is witnessing a
rejuvenated business jet market with rising original equipment and improving
aftermarket fortunes. Furthermore, a strong balance sheet, incremental dividend,
ongoing share repurchase program and a relatively cheap earnings-based valuation
add visibility to the story. However, this is offset by the U.S.
delayed funding authorizations, program execution risk, dependence on
international sales, high exposure to fixed price contracts and high research
and development overhead. Thus we maintain our market Neutral recommendation on
the stock with a target price of $59.00."
JPMorgan Chase initiated coverage on shares of Copano Energy, L.L.C. (NASDAQ:
CPNO). They issued a neutral rating on the stock and set a $35.00 price target.
Piper Jaffray downgraded shares of CenturyLink, Inc. (NYSE: CTL) from an
overweight rating to a neutral rating. Their analysts now have a $42.00 price
target on the stock, down previously from $45.00.
Dawson James downgraded shares of Cytokinetics, Inc. (NASDAQ: CYTK) to an
outperform rating. They wrote, "Although CYTK's programs are still relatively
early, they are based on an understanding of the underlying biology unparalleled
in the industry. In addition, the competitive landscape is characterized by few
opposing programs. Our company valuation is based primarily on the weighted-
probability of the DCF analysis for two tirasemtiv scenarios: approval based on
accelerated approval or a subsequent Phase III trial. We believe there is a 70%
chance of accelerated approval for tirasemtiv ($2.50) and a 30% chance a Phase
III is required ($0.75). We derive our $2 price target from the synthesis of
Zacks reiterated its neutral rating on shares of Delta Air Lines (DAL). They
have a $10.00 price target on the stock. Zacks' analyst wrote, "We are
maintaining our Neutral recommendation on Delta Air Lines. For the July-
September period, the company's performance failed to match our expectations on
both fronts. Additionally, fuel price volatility, unionized labor, new
advertising policy and competitive threats act as major roadblocks for the
company. However, these negative aspects are expected to be negated with Delta's
various initiatives and cost-cutting measures. The company is progressing well
on improving ancillary revenues by adding new features to its services as well
as expanding new products, which are enhancing its value and profitability.
Hence, we believe that Delta, at current levels, displays limited upside
potential and we advice investors to hold onto the stock in the coming days."
Zacks reiterated its neutral rating on shares of Dean Foods Co (DF). They have a
$18.00 price target on the stock. Zacks' analyst wrote, "Owing to effective cost
management, Dean Foods' earnings of $0.33 per share for third-quarter 2012
jumped nearly 83% from year-ago quarter and exceeded the Zacks Consensus
Estimate of $0.28. Bolstered by solid bottom-line performance, the company
raised its full fiscal 2012 earnings guidance to $1.27-$1.32 per share from
$1.18 $1.28 forecasted earlier. Moreover, for the fourth quarter of fiscal
2012, the company anticipates earnings to be between $0.27 and $0.32 per share
compared with year-ago quarters' earnings of $0.27. Further, we believe that the
company's decision to offload its Morningstar business and go for an IPO for its
subsidiary will provide financial flexibility for funding future growth plan
while minimizing debt. However, anticipating an adverse impact on margins due to
rising raw milk prices we prefer to be on the sidelines. In the fourth quarter,
the company is projecting a 20% rise in the raw milk prices over third quarter.
Therefore, we have retained our long-term Neutral recommendation on the stock."
JPMorgan Chase initiated coverage on shares of DCP Midstream Partners, LP (DPM).
They issued a neutral rating on the stock and set a $48.00 price target.
Brean Murray raised its price target on shares of Electronic Arts Inc. (EA) from
$15.00 to $19.00. They have a buy rating on the stock.
Stay on top of analysts' coverage with Analyst Ratings Network's free daily
email newsletter that provides a concise list of analysts' upgrades, downgrades
and initiations. Register at bit.ly/equitybriefdaily
Content and Media Contact: firstname.lastname@example.org
This announcement is distributed by Thomson Reuters on behalf of
Thomson Reuters clients. The owner of this announcement warrants that:
(i) the releases contained herein are protected by copyright and
other applicable laws; and
(ii) they are solely responsible for the content, accuracy and
originality of the information contained therein.
Source: Equity Brief via Thomson Reuters ONE